Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

22.55USD
15 Dec 2017
Change (% chg)

$-0.95 (-4.04%)
Prev Close
$23.50
Open
$23.00
Day's High
$23.75
Day's Low
$22.55
Volume
29,791
Avg. Vol
--
52-wk High
$51.90
52-wk Low
$21.35

Chart for

About

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was... (more)
No analyst recommendations are available for .

Overall

Beta: -0.31
Market Cap(Mil.): $72.86
Shares Outstanding(Mil.): 2.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​

* OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

04 Dec 2017

BRIEF-Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald

* Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​ Source text (http://bit.ly/2gQyRPi) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

19 Oct 2017

BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln

* Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​ Source text : http://bit.ly/2gmIQz2 Further company coverage:

16 Oct 2017

BRIEF-Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​

* Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update

13 Oct 2017

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

02 Oct 2017

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

02 Oct 2017

BRIEF-Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

* Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

15 Sep 2017

BRIEF-Opiant Pharmaceuticals says co and Torreya Partners entered into a supplemental engagement letter

* Opiant Pharmaceuticals Inc - ‍on September 8, co and Torreya Partners entered into a supplemental engagement letter effective September 7​

14 Sep 2017

Earnings vs. Estimates